Motavizumab is an investigational monoclonal antibody that was being considered to help prevent RSV disease.
AstraZeneca has requested withdrawal of the biological license application (BLA) pending at the US Food and Drug Administration (FDA).
MedImmune filed the original BLA on 30 January 2008, and received its first complete response letter (CRL) in November 2008.
MedImmune has decided to discontinue certain Motavizumab development paths and withdraw the prophylaxis BLA from the FDA; however, Motavizumab remains in development for other RSV treatment.
As a result of this decision, AstraZeneca will incur a financial impairment charge of $445m in the fourth quarter 2010 accounts.